CTLA4 and neoplasm: First-generation ICBT primarily targets the CD28/CTLA-4 and the PD-1/PD-L1 signaling pathways, to revitalize functionally suppressed T cells in tumor conditions (detailed mechanisms were summarized in the previous reviews) [4,5].